Optical Imaging of Intratumoral HIF-1 activity to Optimize Treatment Regimens for Chemoradiotherapy

在这里，我和我的同事们进行了一系列光学成像实验来观察肿瘤内HIF-1的活性，并优化了一些可以调节HIF-1活性的放射与抗肿瘤药物的组合，如VEGF中和剂贝伐单抗和HIF-1抑制剂YC-1.1。光学成像实验表明，在治疗1天后，使用vegf中和剂贝伐单抗可暂时诱导肿瘤移植血管正常化并降低其缺氧分数。当在这个时间给予放射治疗时，联合治疗比单独放射治疗明显延迟肿瘤生长。我们发现给药HIF-1抑制剂YC-1可以抑制放射诱导的肿瘤内HIF-1活性的激活，然后显著延迟放射治疗后复发肿瘤的生长。

Here, I and my colleagues performed a series of optical imaging experiments to visualize intratumoral HIF-1 activity, and optimized some combination of radiation with antitumor drugs, which could modulate HIF-1 activity, such as a VEGF neutralizing agent, bevacizumab, and a HIF-1 inhibitor, YC-1.1. Optical imaging experiments showed that administration of a VEGF-neutralizing agent, bevacizumab, temporally induced vascular normalization and decreased hypoxic fraction in tumor xenografts 1 day after the treatment. When radiation treatment was given in this timing, the combined treatment significantly delayed tumor growth compared to radiation therapy alone.2. We found that administration of a HIF-1 inhibitor, YC-1, suppressed radiation-induced activation of intratumoral HIF-1 activity, and then significantly delayed the growth of recurrent tumor after radiation therapy.